ISAL 2023 | The importance of MRD monitoring in patients with AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML), and further comments on the value of improving assays used for MRD detection. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma, Grant/Research support from: Amgen, Xencor, Astex/Taiho, Abbvie, Syros, Prelude, Honoraria from: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma
